Board of Directors

Andrew ElBardissi MD

As a Principal of the Private Transactions team, Dr. ElBardissi joined Deerfield in 2017 to work on structured transactions in Deerfield’s Private Design Funds. Prior to joining Deerfield, Dr. ElBardissi was a Principal at Longitude Capital where he focused on investments in medtech and biotechnology. Prior to Longitude, Dr. ElBardissi was an Associate in J.P. Morgan’s Healthcare Investment Banking practice.

He received residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford University. Dr. ElBardissi has been independently funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, has over 30 publications in leading peer reviewed scientific journals and has presented his research at numerous medical and surgical conferences. He holds an MD from the Mayo Clinic, an MPH in Quantitative Methods from Harvard University, an MBA from Harvard Business School and a BS with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University.

 

Dr. Greg Fiore

Gregory Fiore MD

Dr. Fiore is a Co-Founder and is the President and Chief Executive Officer of Sollis Therapeutics.  He is an entrepreneur and founder of two successful healthcare consulting firms, Fiore Healthcare Advisors and SSI Strategy. Dr. Fiore was previously the Chief Medical Officer of The Medicines Company, a global, commercial-stage biopharmaceutical company focused on hospital products.  Dr. Fiore previously worked as a Strategy Consultant at McKinsey & Company and has held executive roles in several pharmaceutical / biotechnology companies such as Merck, The Medicines Company, and Abbott Laboratories.

Dr. Fiore received Internal Medicine training at Harvard Medical School’s Brigham and Women’s Hospital and Pulmonary / Critical Care training in the Harvard Medical School Pulmonary and Critical Care Fellowship Program. He received his MD degree and was valedictorian at New York Medical College and received a B.S. degree in Zoology from the University of Rhode Island with honors.  

Dr. Fiore serves on several Medical and Business Advisory Committees.  He is on the Executive Board of the Institute of Neuromodulation (ION), the Scientific Advisory Board for Advera Health Analytics, the Business Advisory Board for Advanced Clinical Group, the Editorial Advisory Board of Clinical Leader, and the Executive Committee for the Safety of Oral Anticoagulants (SOAR) Registry. He has previously served on the Board of Dubset Media Holdings.

 

Steven Hochberg MBA

As a Partner on the Private Transactions team, Steve joined Deerfield in 2013 to work on structured transactions in Deerfield’s Private Design Funds. Steve has been a founder and manager of healthcare companies for more than 20 years. 

Since 2004, Steve has managed Ascent Biomedical Ventures, a leading venture capital firm he co-founded focused on early stage investment and development of biomedical companies. 

Since 2011, Steve has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is the Senior Vice Chairman of the Mount Sinai Health System, a $5 billion non-profit healthcare integrated delivery system in New York City.  He graduated from the University of Michigan and earned his MBA from Harvard Business School. 

 

Greg Licholai MD

Greg Licholai, MD is on the faculty at Yale University School of Management, co-director of the Yale Center for Digital Health, and is the Chief Medical Information Officer at PRA Health Sciences, a global drug development service firm.  Previously, he was President and Chief Medical Officer at Castle Creek Pharmaceuticals and responsible for all research and development activities. Earlier he was the founder and President of Elipdera, focused on rare genetic and metabolic diseases, and at Amicus Therapeutics, focused on pharmacological chaperones for rare diseases. He was director of Ventures and Business Development at Medtronic Neurological, where he was responsible for approval of a novel implantable device to treat pediatric dystonia.

He trained at the Brigham and Women’s, Children’s, and Massachusetts General Hospitals, was a Howard Hughes Medical Institute Research Scholar at the National Institutes of Health, performed research in molecular genetics at Yale University and worked in molecular oncology at Rockefeller University. He received a B.S. from Boston College, Pre-Medical studies at Columbia University, an M.D. from Yale Medical School and an M.B.A from Harvard Business School. He is on the advisory boards of the National Tay Sachs and Allied Disease Foundation and the Partnership for Palliative Care, Yale Healthcare Conference and Yale Center for Biomedical Innovation and Technology and a lecturer at the Harvard Innovation Lab as well as Yale School of Management.

 

Richard W. Mott

Mr. Mott is currently a principal in Walkabout Consulting LLC, a management consulting and private equity firm.

Mr. Mott served as President and Chief Executive Officer and Director of Kyphon Inc., a NASDAQ-listed global medical device company focused on minimally invasive spinal therapies, through its acquisition by Medtronic, Inc. in late 2007. Prior to Kyphon, Mr. Mott held several executive positions, most recently as Chief Operating Officer at Wilson Greatbatch Technologies, Inc., a NYSE-listed medical technology company as well as executive operating roles within the Bristol-Myers Squibb Company.

Mr. Mott currently serves on the Boards of Directors of the following companies: Keratin Biosciences, Inc., Relievant Medsystems, Treace Medical Concepts, Conventus Orthopaedics, Arsenal Medical, Vertiflex, Inc., and Sollis Therapeutics.

Mr. Mott is a Director/Owner of VFD Technologies, a private equity firm that invests in, acquires and owns manufacturing businesses with unique technical capabilities that specialize in high-performance materials.

Mr. Mott is the previous recipient of the Ernst & Young Entrepreneur of the Year Award and the Frost & Sullivan Technology Leadership of the Year Award and the Phoenix Lifetime Achievement Award. Mr. Mott also lectures on Leadership and Entrepreneurialism in leading academic and business forums.


Mr. Mott holds a B.S. in Ceramic Engineering from Alfred University and is a Graduate of Harvard University’s Advanced Management Program.

 

Kevin Wasserstein MBA

Kevin Wasserstein specializes in building medical device companies through their entire life cycle, from concept to commercialization.

Kevin is the CEO and Co-Founder of the Neurotechnology Innovations Translator (NIT), a unique translational center in Columbus, Ohio, whose mission is to form or attract, develop, and commercialize pioneering neurotechnology companies from around the globe to improve patient well-being. With capital and service commitments of over $160M, the NIT catapults selected companies with a robust ecosystem of expertise and resources including capital for investment, scientific and clinical innovation, engineering development, pre-clinical and clinical trialing, and manufacturing and regulatory services.

Prior to the NIT, Kevin spent over a decade as a Managing Director at Versant Ventures, where he focused on investing in and building early stage medical device companies.